Key US Entresto Barriers Are PA Process & Co-Payments – BMT Poll

A BioMedTracker poll canvassing 23 US-based cardiologists about the main clinical and reimbursement hurdles causing the slow uptake there of Novartis's heart failure drug Entresto (valsartan/sacubitril) suggests insurance issues - namely pre-authorization and high co-payments - are the key causes. More than a third of respondents also listed reluctance to switch patients doing well on current medications, while only 9-13% listed lack of confidence about efficacy, concerns about hypotension, or titration issues as important barriers.